Dropbox Inc vs Definium Therapeutics Inc. Common Shares — how do they compare? Dropbox Inc trades at $34.15 (market cap $7.19B), while Definium Therapeutics Inc. Common Shares trades at $34.01 (market cap $4.71B). The key difference: Dropbox Inc is the larger of the two by market cap, and Dropbox Inc is trading nearer its 52-week high, Definium Therapeutics Inc. Common Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dropbox Inc for 97 Days and Definium Therapeutics Inc. Common Shares for 0 Days on average.
| DBX | DFTX | |
|---|---|---|
Market Cap | $7.19B | $4.71B |
Volume | 2,804,312 | 1,966,636 |
Sector | Technology | Health |
52-Week High | $37.74 | $48.45 |
52-Week Low | $22.06 | $10.68 |
Typical Hold Time | 97 Days | 0 Days |
Enterprise Value | $10.05B | $3.67B |
Signals from Pluang's Aura AI — not financial advice
Dropbox (DBX) trades at $34.14, up 1.22% on the day, with a bearish technical signal and mixed analyst ratings. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $0.728. Revenue remains stable around $2.5B annually, with a high gross margin of 79.72%, but net cash flow turned negative in 2025 due to significant financing outflows. Recent news highlights insider selling and a security breach affecting 5,000 accounts.
The outlook is cautious; while profitability is solid, stagnant revenue growth and high debt levels pose risks. The consensus price target of $26.83 suggests downside potential. Investor sentiment is divided, with technical indicators signaling bearish pressure. Key risks include competitive threats and execution challenges in a mature market.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.
Read more on DBX →Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →